Risk of severe COVID‐19 in patients treated with IBD medications : a French nationwide study
Summary Background Recently, the SECURE‐IBD study, based on a physician‐reported registry, suggested that thiopurines, either alone or combined with anti‐TNF, may increase risk of severe COVID‐19. Aims To compare the risk of severe COVID‐19 according to IBD medications in a large and unselected population. Methods Using the French national health data system, the risks of hospitalisation and of death or mechanical ventilation for COVID‐19 from 15 February 2020 to 31 August 2020 in IBD patients were compared according to IBD treatment (immunomodulators and biologics), using multivariable Cox models adjusted for socio‐demographic characteristics, budesonide/corticosteroids and aminosalicylates use, and comorbidities. Results Among 268 185 IBD patients, 600 were hospitalised for COVID‐19 and 111 of them died or were mechanically ventilated (including 78 deaths). In multivariable analysis, the risk of hospitalisation for COVID‐19 did not differ according to IBD treatment category, with adjusted Hazard Ratios (aHR, unexposed patients used as reference) of 0.94 (95%CI: 0.66‐1.35) for immunomodulator monotherapy, 1.05 (0.80‐1.38) for anti‐TNF monotherapy, 0.80 (0.38‐1.69) for anti‐TNF combination therapy, 1.06 (0.55‐2.05) for vedolizumab and 1.25 (0.64‐2.43) for ustekinumab. Similarly, the risk of death or mechanical ventilation for COVID‐19 did not differ according to IBD treatment. Conclusions Immunomodulators and biologics prescribed in patients with IBD do not appear to increase the severity of COVID‐19 infection..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:54 |
|---|---|
| Enthalten in: |
Alimentary Pharmacology & Therapeutics - 54(2021), 2, Seite 160-166 |
| Beteiligte Personen: |
Meyer, Antoine [VerfasserIn] |
|---|
| BKL: |
|---|
| Anmerkungen: |
Copyright © 2021 John Wiley & Sons Ltd |
|---|
| Umfang: |
7 |
|---|
| doi: |
10.1111/apt.16410 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY002339757 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY002339757 | ||
| 003 | DE-627 | ||
| 005 | 20230307114638.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230210s2021 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/apt.16410 |2 doi | |
| 028 | 5 | 2 | |a APT_APT16410.xml |
| 035 | |a (DE-627)WLY002339757 | ||
| 035 | |a (WILEY)APT16410 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.38 |2 bkl | ||
| 100 | 1 | |a Meyer, Antoine |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Risk of severe COVID‐19 in patients treated with IBD medications |b a French nationwide study |
| 264 | 1 | |c 2021 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Copyright © 2021 John Wiley & Sons Ltd | ||
| 520 | |a Summary Background Recently, the SECURE‐IBD study, based on a physician‐reported registry, suggested that thiopurines, either alone or combined with anti‐TNF, may increase risk of severe COVID‐19. Aims To compare the risk of severe COVID‐19 according to IBD medications in a large and unselected population. Methods Using the French national health data system, the risks of hospitalisation and of death or mechanical ventilation for COVID‐19 from 15 February 2020 to 31 August 2020 in IBD patients were compared according to IBD treatment (immunomodulators and biologics), using multivariable Cox models adjusted for socio‐demographic characteristics, budesonide/corticosteroids and aminosalicylates use, and comorbidities. Results Among 268 185 IBD patients, 600 were hospitalised for COVID‐19 and 111 of them died or were mechanically ventilated (including 78 deaths). In multivariable analysis, the risk of hospitalisation for COVID‐19 did not differ according to IBD treatment category, with adjusted Hazard Ratios (aHR, unexposed patients used as reference) of 0.94 (95%CI: 0.66‐1.35) for immunomodulator monotherapy, 1.05 (0.80‐1.38) for anti‐TNF monotherapy, 0.80 (0.38‐1.69) for anti‐TNF combination therapy, 1.06 (0.55‐2.05) for vedolizumab and 1.25 (0.64‐2.43) for ustekinumab. Similarly, the risk of death or mechanical ventilation for COVID‐19 did not differ according to IBD treatment. Conclusions Immunomodulators and biologics prescribed in patients with IBD do not appear to increase the severity of COVID‐19 infection. | ||
| 700 | 1 | |a Semenzato, Laura |4 aut | |
| 700 | 1 | |a Zureik, Mahmoud |4 aut | |
| 700 | 1 | |a Weill, Alain |4 aut | |
| 700 | 1 | |a Carbonnel, Franck |4 aut | |
| 700 | 1 | |a Dray‐Spira, Rosemary |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Alimentary Pharmacology & Therapeutics |g 54(2021), 2, Seite 160-166 |w (DE-627)WLY002324040 |x 13652036 |7 nnns |
| 773 | 1 | 8 | |g volume:54 |g year:2021 |g number:2 |g pages:160-166 |g extent:7 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-ASE | ||
| 936 | b | k | |a 44.38 |q ASE |
| 951 | |a AR | ||
| 952 | |d 54 |j 2021 |e 2 |h 160-166 |g 7 | ||